AIDS Research and Therapy · Nov 18, 2026
Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or protease inhibitor-based antiretroviral therapy: a 144-week analysis from the VISEND Trial in Zambia
By Siwingwa M, Mutale W, Sinkala M et al.
Background MetS has emerged as a growing concern among PLHIV receiving ART in Sub-Saharan Africa (SSA), and the metabolic changes may differ across ART regimens. We aimed to assess longitudinal changes in the odds of MetS across three ART regimens among PLHIV, using data from the VISEND trial over 144 weeks. Methods We conducted a longitudinal cohort study within the VISEND trial, involving 899 adults living with HIV in Zambia. Participants were randomized to one of three ART regimens: a protease inhibitor-based arm (n = 284), tenofovir alafenamide/emtricitabine/dolutegravir (TAFED, n = 295), or tenofovir/lamivudine/dolutegravir (TLD, n = 320). MetS was assessed using ATP III criteria over 144 weeks. We applied generalized estimating equations to assess differences in MetS odds across the three ART regimens and estimate adjusted odds ratios (ORs), with marginal predictions used to estimate regimen-specific odds. Results Median age was 44 years (IQR 37–50), and 61.6% were female. MetS prevalence rose over 144 weeks, peaking at week 120 (TLD: 36.6%; TAFED: 35.2%; PI-based regimens: 26.0%). In adjusted models, odds of MetS varied across regimens: TLD showed higher odds (aOR = 1.33, 95% CI: 1.05–1.78; p = 0.036), while TAFED’s association was attenuated (aOR = 1.24, 95% CI: 0.97–1.66; p = 0.127). No significant difference emerged between TAFED and TLD. Women had higher odds (aOR = 1.66, 95% CI: 1.16–2.39; p = 0.006). Older age and higher CD4 count were independently associated with higher odds of MetS. Conclusions MetS increased progressively over 144 weeks across the three ART regimens. TLD was independently associated with higher odds, while TAFED was not significant after adjustment. Age and CD4 count independently associated with MetS, underscoring host factors and immune recovery. Routine metabolic screening and integrated cardiovascular odds management should accompany DTG scale-up. Trial registration: PACTR201904781300573.